CARB-X is funding the development of avails medical’s rapid antibiotic susceptibility testing technology
CARB-X is funding Avails Medical, a Menlo Park, CA, USA, diagnostics company, to develop an electronic antibiotic susceptibility testing (AST) device to speed up health care providers’ ability to determine the most effective antibiotic treatment for serious and life-threatening blood infections. The new device will use electronic biosensors that fit onto commercially available AST panels. From a positive blood culture sample, it aims to identify the most effective antibiotics to treat the infection within four hours rather than days.
Display your AMR Technology, Product and Service
Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.